Ocugen to Begin Phase III Study on Eye Drug in Canada, Stock Up
ZacksOCGN receives Health Canada’s No Objection Letter to begin a phase III study on OCU400 for treating retinitis pigmentosa. Shares rise.
OCGN receives Health Canada’s No Objection Letter to begin a phase III study on OCU400 for treating retinitis pigmentosa. Shares rise.